Introduction
Humans express four antigen-presenting proteins (CD1a, CD1b, CD1c and CD1d) belonging to the CD1 family, which present lipid-based molecules to T cells via their T cell receptors (TCRs).
1 CD1a
differs from the other CD1 molecules owing to its constitutive, high-density expression on dendritic cells, termed Langerhans cells, in the skin and mucosa. 2 Moreover, distinct from the other human CD1 molecules, CD1a possesses a cytoplasmic tail that lacks lysosomal targeting motifs. Thus, CD1a
localizes predominantly at the cell surface where it can capture foreign or exogenous lipids. The only extensively characterized type of foreign lipidic molecule that activates CD1a-restricted T cells is a family of lipopeptides isolated from Mycobacterium tuberculosis, termed dideoxymycobactins (DDMs).
3
The initial discovery of the DDMs was achieved through bioassay-guided fractionation using a single T cell clone (CD8-2) obtained through stimulation and expansion with a chloroform/methanol M.
tuberculosis extract.
lipopeptide showed the fatty acyl chain buried in the A′ pocket of CD1a with the peptide protruding from the surface of CD1a, where it presumably contacts the TCR. 5 The recent development of CD1a tetramers and dextramers that bind directly to polyclonal T cells in the ex vivo setting has allowed the detection and isolation of DDM-reactive T cell clones from small cohorts of tuberculosis patients. 6 This suggests that CD1a-DDM reactive T cells occur in unrelated individuals and that CD1a-DDM tetramers may be useful reagents for the ex vivo diagnosis of M. tuberculosis infection. Furthermore, the existence of polyclonal T cells in small human cohorts raises the possibility that DDMs could be used to immunize or stimulate T cell responses in tuberculosis patients. 6 However, the key obstacle to these lines of new medical technology development is the absence of an abundant supply of DDM.
DDMs are extremely potent, but comprise less than 10 parts per million of the cell wall mass of M.
tuberculosis, a pathogen for which the laboratory cultivation is slow and cumbersome because it must be grown in biosafety level 3 conditions. Thus, isolation in high yield from natural sources remains impractical. 3 The key challenge for chemical synthesis is that naturally occurring DDMs possess a complex depsipeptide backbone bearing a range of saturated and unsaturated fatty acyl groups linked through an amide to the ϵ-amino group of a lysine residue, and an unusual α-methylserine-derived angular methyl group. The structure of the most reactive compound, DDM-838 (1, Figure 1 ) was proposed through mass spectrometric and NMR analysis, 3a as well as the preparation of a range of possible stereoisomers and matching of their spectroscopic data and biological activity to the natural product, 3b and is consistent with the stereochemistry of the biosynthetically related mycobactins, ironchelating hydroxamic acid siderophores.
A previous synthetic approach 3b to DDM-838 used solid-phase peptide chemistry to provide sufficient material to help clarify the structure of the natural product, yet the poor overall yield provided only sub-milligram quantities that are insufficient for in vivo studies. Prior work demonstrated that the correct stereochemistry at positions a and c (Figure 1 ), and the angular methyl group at position a are necessary for activating the DDM-reactive T cell clone CD8-2, and that natural DDMs lacking the unsaturation in the acyl chain are at least 10-fold less potent for T cell activation.
In the present work we investigate solution-based peptide-coupling approaches for the preparation of milligram quantities of DDM-838. Through careful isolation of by-products produced in this process, we identify difficulties with the establishment of the key ester linkage that occurs with partial epimerization at lysine, a problem that may have occurred in the previous approach of Young and coworkers (unpublished). This and other problems were overcome by the development of a new route that creates the challenging ester linkage through a Mitsunobu coupling and allows the preparation of milligram quantities of DDM-838 (1). Through the isolation of stereochemical isomers of DDM-838
(2-4) we have explored structure-activity relationships in antigen recognition by the prototypical DDM-reactive T cell clone CD8-2, as well as new DDM-reactive clones, and demonstrate the importance of peptide and lipid stereochemistry for TCR recognition and T cell activation.
Results and Discussion

Total synthesis of DDM-838
Young and co-workers reported the synthesis of DDM-838 and analogues, emphasizing solid-phase approaches. 3b For the assembly of DDM-838 itself, a linear depsipeptide bearing the fatty acyl chain was assembled on Fmoc-Lys Sasrin (Fmoc=9-fluorenylmethyloxycarbonyl) resin. Following release of the depsipeptide from the resin, the terminal lysine was cyclized to form the caprolactam moiety. After extensive HPLC purification, this approach yielded only trace quantities of DDM-838 (around 95 μg or β % overall yield), which we verified independently. As this synthesis was conducted on a solid phase, it is difficult to identify the yield-limiting steps. In a solution-phase approach, used for the synthesis of analogues that lacked the distinguishing α-methyl group, an ϵ-amino-protected deoxymycobactic acid was coupled to deoxycobactin, and the depsipeptide was deprotected prior to attaching the fatty acyl chain. This resulted in low yields for both attachment of the fatty acyl chain and for formation of the ester linkage. Moreover, unexpected doubling of signals in NMR spectra of advanced intermediates was attributed to the presence of rotational isomers, but could alternatively reflect the formation of undefined stereoisomers. With the above issues in mind, we initially sought to develop a solution-based synthesis of DDM-838 broadly inspired by this earlier study, 3b but with the intention to fully characterize all intermediates and identify yield-limiting steps in order to identify an improved synthetic approach.
The required building-block fragments deoxymycobactic acid 13, deoxycobactin 16, and Z-C20:1 fatty acid 20 were prepared by optimization of the previously described literature approaches. 3b Oxazoline acid 11 was prepared from α-methyl-L-serine 5, by protection as the methyl ester 6, which was condensed with 2-benzyloxysalicylic acid 8 using COMU to afford amide 9 (Scheme 2 a). 7 Cyclization to the oxazoline 10 proceeded smoothly with XtalFluor-M in CH2Cl2. 8 Saponification of the ester of 10 with LiOH afforded the O-benzyl-protected acid 11, which was coupled with NH2-LLys(Boc)OMe using EDC⋅HCl/HOAt/DMAP (EDC=1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide; HOAt=1-hydroxy-7-azabenzotriazole; DMAP=4-dimethylaminopyridine).
Saponification of 12 afforded deoxymycobactic acid 13. Next, deoxycobactin 16 was prepared by the coupling of (R)-3-hydroxybutyric acid 14 and L-α-amino-ϵ-caprolactam hydrochloride 15 in the presence of EDC⋅HCl/HOAt/DMAP (Scheme 2 b). 3b Finally, the Z-C20:1 fatty acid 20 was synthesized using Ando's reagent, 9 which enables a highly Z-selective Horner-Emmons-Wadsworth The above work, and an alternative approach utilizing a different order of assembly that gave
improved yields yet also suffered from similar problems (see Supporting Information for details),
highlighted two key problems that likely contributed to the low yield of the prior solid-and solutionbased syntheses of DDM-838. 3b The first is the difficulty of effecting the esterification of the 3-hydroxybutyramide, which occurred at best in only moderate yield and was complicated by epimerization at the central lysine. The difficulty of this coupling likely arises from the sterically congested nature of the linkage, between an α-branched acid, and a secondary alcohol. The propensity for epimerization at the central lysine during esterification of the 3-hydroxybutyramide group means that the stereochemistry at this position had not been unambiguously secured, although the biosynthetic relationship of DDM-838 to the mycobactins allows assumption of the L-configuration.
11
The second problem was the unexpected isomerization of the unsaturated fatty acyl chain, and the sometimes contamination with a trifluoroacetamide by-product.
We initially focussed on solving the problem experienced with the unexpected formation of E and Z isomers upon acylation of S-and R-22 with Z-C20:1 acid 20, and the formation of the trifluoroacetamide by-product. By conversion of the trifluoroacetate salt of compound 22 to the free base, prior to acylation, we were able to avoid trifluoroacetamide formation. Treatment of a pure Z-C20:1-Lys model with iPr2NEt did not result in double bond isomerization, suggesting that isomerization was occurring to the activated acyl intermediate. Attempts to acylate the model amine (Bz-L-Lys-OMe) using DIC/HOAt/DMAP, without iPr2NEt or with pyridine, still led to double bond isomerization, suggesting that base-catalyzed isomerization is faster than acylation of lysine. Hocking has shown that double bond isomerization of cis-crotonoyl chloride during reaction with ammonia does not occur when ammonia is passed over the surface of an ethereal solution of the acid chloride. 12 Inspired by this precedent, we examined pre-forming the activated ester by combining DIC and Z-C20:1 20 in CH2Cl2, followed by addition of a CH2Cl2 solution of Bz-L-Lys-OMe, which afforded the cis-amide as the sole product.
To overcome the problem with epimerization at the central lysine, a Mitsunobu reaction was explored to form an ester bond and interchange the roles of the acid and alcohol to nucleophile and electrophile, respectively, thereby potentially alleviating the steric demands in forming this linkage. In 
Immunological investigation of CD1a-restricted T cell clones
We explored the ability of our synthetic compounds to mediate binding interactions between CD1a
and TCRs using a series of immunological assays that measure either the biological potency of compounds in cellular assays (through the expression of activation marker CD69) or the mechanistic basis of TCR binding to CD1a-lipopeptide complexes (through tetramer staining and flow cytometry).
We studied several CD1a-restricted TCR + clones including autoreactive clones that recognize CD1a alone, and those recognizing CD1a presenting foreign DDM and related antigens. Initially, we permissive self-lipids, 17 but less brightly stained with CD1a tetramers treated with compounds 1-4. Structural studies have revealed that the BK6 TCR binds to the A′ roof of CD1a, whereas nonpermissive ligands such as sphingomyelin and sulfatide protrude from the A′ cleft and disrupt the BK6 TCR-CD1a contact zone. 17 An X-ray structure of a silylated mycobactin analogue revealed the alkyl chain inserted deep within the A′ pocket of the antigen-binding groove, with the peptide folded over in the F′ pocket and with both the caprolactam and salicyl moieties extending outward to the predicted plane of the TCR contact. 5 This binary structure, as well as molecular modelling studies of CD1a-DDM-838 complexes, 3 predict that the peptide moiety might block approach of the BK6 TCR to CD1a, based on the known docking mode of BK6 with CD1a. 17 This prediction is supported by our results, which also provides evidence that all four DDM analogues bind to CD1a. Furthermore, Jurkat cells expressing the CD8-2, Clone 8 and Clone 15 TCRs fail to bind to CD1a tetramers loaded with self-lipids that are permissive to CD1a-BK6 TCR binding. This suggests an alternative TCR recognition mode compared to BK6 in which the peptide moiety likely protrudes from the groove to facilitate rather than block TCR binding.
Conclusions
Our data reveal a conserved spectrum of T cell recognition of the panel of DDM isomers by a set of three unrelated CD1a-DDM-reactive TCRs. The natural form, DDM-838 1 is the most potent, whereas compound 2, which varies in the lipid stereochemistry, maintained significant, albeit reduced, activity relative to 1. This result is reminiscent of the effect observed after saturating the acyl chain of DDM-838 to generate DDM-840, 3a demonstrating the importance of the cis-Δ 2 -unsaturation of DDM-838 for its potent antigenicity. The stereochemistry and location of this unsaturation (at C2) is unusual and is generated by mycobactin synthase N (MbtN). 19 Although the biochemical function of the unsaturation is unknown, this work confirms its importance for antigen recognition.
The inversion of stereochemistry at the lysine of the depsipeptide backbone compromises the activity of lipopeptide and this was reflected in the low reactivity of the DDM-reactive TCRs to CD1a-compound 3 tetramers, similar to prior studies of DDM-838 varying at either the oxazoline or butyrate moieties (positions a and c, Figure 1 ). 3b The strong attenuation of TCR binding and T cell activation by compound 4, which is both epimerized at the central lysine and contains the trans acyl chain, reinforces these structure-activity relationships. Collectively, these results reveal that the stereochemistry of the depsipeptide backbone is important for DDM-recognition by CD1a-restricted TCRs, and that variation in stereochemistry or saturation in the lipid chain leads to partial attenuation of reactivity. The recognition of DDM-838 1 by three distinct T cell clones supports the development of these compounds to target the naturally occurring polyclonal T cells present in latent tuberculosis infected patients. 6 The ability to synthesize larger quantities of DDM-838 by the solution-phase method described herein makes possible structural and functional studies of TCR recognition of CD1a-DDM-838 complexes, as well as in vivo studies that use DDM as a vaccine component or recall antigens for immunodiagnosis of tuberculosis.
Experimental Section Expression and purification of CD1a
CD1a was expressed by recombinant methods in a mammalian expression system by cloning of constructs encoding CD1a and 2-microglobulin in a pHLsec vector 20 as carboxyterminal fusions with the leucine zippers Jun (CD1a) and Fos ( 2-microglobulin) and a "post-zipper" BirA-His6 tag for . To ensure each lipopeptide was completely solubilized, 12 rounds of sonication (1 h, water bath temperature 25-45 °C), vortex (10 sec) and freezing at −β0 °C (β0 mins) were performed until the mixture was a homogenous suspension.
Production of CD1a-restricted Jurkat 76 cell lines
CD1a-restricted BK6, CD8-2, Clone 8, Clone 15 and control MR1-restricted M33.6423 Jurkat 76 cells were generated as described 24 using retroviral transduction whereby green fluorescent protein and an antibody to CD3ϵ (anti-CD3ϵ; UCHT1; BD Biosciences) signified successful transduction.
Parental Jurkat 76 cells lack endogenous TCR α-chains and -chains, 22 and therefore TCR specificity is conferred by the transgene. These have recently been tested and confirmed to be free of Mycoplasma.
Loading of CD1 a, production of CD1 a tetramers and staining of Jurkat 76 cells with CD1 a tetramers
Soluble mammalian CD1a samples were enzymatically biotinylated with BirA biotin ligase as previously described. 21 Biotinylated CD1a was loaded overnight with each DDM isomer at a molar ratio of 1:6. DDM-loaded biotinylated CD1a monomers were tetramerized with streptavidinphycoerythrin (BD Biosciences). 3×10 4 CD1a-restricted BK6, CD8-2, Clone 8, Clone 15 and control MR1-restricted M33.64 Jurkat 76 cells, generated as described above were incubated with anti-CD3ϵ (UCHT1; BD Biosciences) and CD1a-DDM tetramers for 25 mins and CD1a tetramer staining intensity determined on the CDγϵ + Jurkat 76 cells, and were analyzed with an LSR Fortessa (BD Biosciences). Data were processed with FlowJo software (TreeStar).
Assay of activation of the human BK6 and CD8-2 Jurkat 76 cell lines
CD1a-restricted BK6 and CD8-2 Jurkat 76 cells were generated as described above. CD1a-expressing C1R cells were generated as previously described. 
Activation of human T cell clone CD8-2 by three sources of DDM-838 (1)
CD1a-expressing K562 myeloid cells have been described previously and are routinely tested by flow cytometry to confirm surface CD1a expression. 15 DDM-838 from solid-phase synthesis was provided by Dr David Young using the reported method. 3b Natural DDM was purified from M.
tuberculosis H37Ra as described previously 3b and characterized by electrospray ionization mass spectrometry to be a mixture of DDM-8γ8 (75 %) and DDM-840 (β5 %). The concentrations of absorbance at 306 nm, normalized to absorbance of 80 μMsolid-phase DDM-838. 5×10 4 CD8-2 T cells were incubated with 2.5×10 4 CD1a-expressing K562 cells and serial dilutions of DDM-838 in 150 μL T cell media for up to 24 hr at γ7 °C. Secreted IFNγ in the undiluted cell culture media was quantified by standard sandwich ELISA using human IFNγ antibody clones 2G2 (Thermo-Fisher), biotin-conjugated B133.5 (Thermo-Fisher) and streptavidin horse radish peroxidase (BD Pharmingen). Absorbance was measured at 405 nm using a VersaMax plate reader (Molecular
Figure 2
Synthetic and natural DDM-838 possess equivalent ability to activate the native CD8-2 T cell clone. 
